Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Excluded: GNA11 mutation

Excluded: GNAQ mutation

Allowed: BRAF targetable mutation

Must have received: anti-PD-1 therapy — systemic therapy for melanoma

must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody

Must have received: anti-PD-L1 therapy — systemic therapy for melanoma

must have experienced documented radiographic disease progression after systemic therapy containing a programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) blocking antibody

Must have received: ICI-based regimen — systemic therapy for NSCLC

relapsed or are refractory to approved systemic therapies (approved ICI-based regimen for all appropriate participants and/or an approved targeted therapy for known molecular abnormalities if applicable to their disease)

Cannot have received: second line cytotoxic chemotherapy

Exception: if already received cytotoxic chemotherapy in the first line setting

must not have been exposed to any second line cytotoxic chemotherapy if they have already received cytotoxic chemotherapy in the first line setting

Cannot have received: BRAF inhibitor

Exception: Participants must not have disease progression on a BRAF/MEK inhibitor that was given as the most recent line of therapy

Participants must not have disease progression on a BRAF/MEK inhibitor that was given as the most recent line of therapy

Cannot have received: MEK inhibitor

Exception: Participants must not have disease progression on a BRAF/MEK inhibitor that was given as the most recent line of therapy

Participants must not have disease progression on a BRAF/MEK inhibitor that was given as the most recent line of therapy